Abstract
The protein adduct carboxyethylpyrrole (CEP) is present in age-related macular degeneration (AMD) eye tissue and in the blood of AMD patients at higher levels than found in age-matched non-AMD tissues. Autoantibodies to CEP are also higher in AMD blood samples than in controls. To test the hypothesis that this hapten is causally involved in initiating an inflammatory response in AMD, we immunized C57BL/6J mice with mouse serum albumin (MSA) adducted with CEP. Immunized mice develop antibodies to CEP, fix complement component-3 in Bruch’s membrane, accumulate drusen below the retinal pigment epithelium during aging, show decreased a- and b-wave amplitudes in response to light, and develop lesions in the retinal pigment epithelium mimicking geographic atrophy, the blinding end-stage condition characteristic of the dry form of AMD. Inflammatory cells are present in the region of lesions and may be actively involved in the pathology observed. We conclude that early immunization of mice with CEP-adducted MSA sensitizes these animals to the ongoing production of CEP adducts in the outer retina where DHA is abundant and the conditions for oxidative damage are permissive. In response to this early sensitization, the immune system mounts a complement-mediated attack on the cells of the outer retina where CEP adducts are formed. This animal model for AMD is the first that was developed from an inflammatory signal discovered in eye tissue and blood from AMD patients. It provides a novel opportunity for dissecting the early pathology of AMD and the immune response contributing to this disorder. The availability of a mouse with a mechanistically based AMD-like disease that progresses rapidly is highly desirable. Such a model will allow for the efficient preclinical testing of the much-needed therapeutics quickly and inexpensively.
This is a preview of subscription content, access via your institution.




References
Javitt JC, Zhou Z, Maguire MG, Fine SL, Willke RJ (2003) Ophthalmol 110:1534–1539
Augood C, Vingerling JR, de Jong PT, Chakravarthy U, Seland J, Soubrane G, Tomazzoli L, Topouzis F, Bentham G, Rahu M, Vioque J, Young IS, Fletcher AE (2006) Arch Ophthalmol 124:529–535
Curcio C, Millican C, Bailey T, Kruth H (2001) Invest Ophthalmol Vis Sci 42:265–274
Hussain A, Rowe L, Marshall J (2002) J Opt Soc Am A Opt Image Sci Vis 19:166–172
Moore D, Hussain A, Marshall J (1995) Invest Ophthalmol Vis Sci 36:1290–1297
Bressler SB, Maguire MG, Bressler NM, Fine SL (1990) Arch Ophthalmol 108:1442–1447
Sarks SH, van Driel D, Maxwell L, Killingsworth M (1980) Trans Ophthalmol Soc UK 100:414–422
Vinding T (1990) Acta Ophthalmol 68:410–414
Holz FG, Bellman C, Staudt S, Schutt F, Volcker HE (2001) Invest Ophthalmol Vis Sci 42:1051–1056
Hollyfield JG, Crabb JW, Salomon RG (2003) Adv Exp Med Biol 533:83–89
Crabb JW, Miyagi M, Gu X, Shadrach KG, West KA, Sakaguchi H, Kamei M, Hasan A, Yan L, Rayborn ME, Salomon RG, Hollyfield JG (2002) Proc Natl Acad Sci USA 99:14682–14687
Sakaguchi H, Miyagi M, Shadrach KG, Rayborn ME, Crabb JW, Hollyfield JG (2002) Exp Eye Res 74:547–549
Bando H, Shadrach KG, Rayborn ME, Crabb JW, Hollyfield JG (2007) Exp Eye Res 84:135–142
Rayborn ME, Sakaguchi H, Shadrach KG, Crabb JS, Crabb JW, Hollyfield JG (2006) Adv Exp Med Biol 572:75–78
Nakata K, Crabb JW, Hollyfield JG (2005) Exp Eye Res 80:821–826
Johnson LV, Leitner WP, Staples MK, Anderson DH (2001) Exp Eye Res 73:887–896
Hageman GS, Mullins RF (1999) Mol Vis 5:28–37
Anderson DH, Mullins RF, Hageman GS, Johnson LV (2002) Am J Ophthalmol 134:411–431
Hageman GS, Luthert PJ, Chong NH, Johnson LV, Anderson DH, Mullins RF (2001) Prog Retina Eye Res 20:705–732
Johnson LV, Ozaki S, Staples ML, Erickson PA, Anderson DH (2000) Exp Eye Res 70:441–449
Doyne RW (1989) Trans Ophthalmol Soc U K 19:71–71
Gass JDM (1987) Stereoscopic atlas of macular diseases. CV Mosby, St. Louis
Meyers SM, Zachary AA (1988) Arch Ophthalmol 106:651–653
Seddon JM, Ajani UA, Mitchell BD (1997) Am J Ophthalmol 123:199–206
Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, Henning AK, SanGiovanni JP, Mane SM, Mayne ST, Bracken MB, Ferris F, Ott J, Barnstable C, Hoh J (2005) Science 308:385–389
Edwards AO, Ritter R, Abel KJ, Manning A, Panhuysen C, Farrer LA (2005) Science 308:421–424
Hageman GS, Anderson DH, Johnson LV, Hancox LS, Taiber AJ, Hardisty LI, Hageman JL, Stockman HA, Borchardt JD, Gehrs KM, Smith RJ, Silvestri G, Russell SR, Klaver CC, Barbazetto I, Chang G, Yannuzzi LA, Barile GR, Merriam JC, Smith RT, Olsh AK, Bergeron J, Zernant J, Merriam JE, Gold B, Dean M, Allikmets R (2005) Proc Natl Acad Sci U S A 102:7227–7232
Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, Gallins P, Spencer KL, Kwan SY, Noureddine M, Gilbert JR, Schnetz-Boutaud N, Agarwal A, Postel EA, Pericak-Vance MA (2005) Science 308:419–421
Gold B, Merriam JE, Zernant J, Hancox LS, Taiber AJ, Gehrs KM, Cramer K, Neel J, Bergeron J, Barile GR, Smith RT, Group AGCS, Hageman GS, Dean M, Allikmets R (2006) Nature Genet 38:458–462
Gu X, Meer SG, Miyagi M, Rayborn ME, Hollyfield JG, Crabb JW, Salomon RG (2003) J Biol Chem 278:42027–42035
Seddon JM, Willett WC, Speizer FE, Hankinson SE (1996) J Am Med Assoc 276:1141–1146
Klein RJ, Klein BE, Cruickshanks KJ (1999) Prog Retin Eye Res 18:371–389
Snow K, Seddon JM (1999) Ophthalmic Epidemiol 6:125–143
Christen WG, Glynn RJ, Manson JE, Ajani UA, Buring JE (1996) JAMA 276:1147–1151
Smith W, Mitchell P, Leeder SR (1996) Arch Ophthalmol 114:1518–1523
Solberg Y, Rosner M, Belkin M (1998) Surv Ophthalmol 42:535–547
AREDS RG (2001) Arch Ophthalmol 119:1439–1452
Fliesler SJ, Anderson RE (1983) Prog Lipid Res 22:79–131
Anderson RE, Lissandrello PM, Maude MB, Matthes MT (1976) Exp Eye Res 23:149–157
Kaur K, Salomon RG, O’Neil J, Hoff H (1997) Chem Res Toxicol 10:1387–1396
Gu X, Sun M, Hazen SL, Crabb JW, Salomon RG (2003) J Org Chem 68:3749–3761
Hollyfield JG, Bonilha VL, Lu L, Rayborn ME, Yang X, Shadrach KG, Ufret RL, Salomon RG, Perez VL (2008) Nat Med 14:194–198
Peakman M, Senaldi G, Vergan D (1989) J Clin Pathol 42:1018–1025
Mombaerts P, Iacomini J, Johnson R, Herrup K, Tonegawa S, Papaioannou V (1992) Cell 68:869–877
Anderson RE (1970) Exp Eye Res 10:339–344
LaVail MM (1976) Exp Eye Res 23:277–280
Besharse JC, Hollyfield JG (1979) Invest Ophthalmol Vis Sci 18:1019–1024
Gordon W, Rodriguez de Turco E, Bazan N (1992) Curr Eye Res 11:73–83
Rodriguez de Turco E, Parkins N, Ershov A, Bazan N (1999) J Neurosci Res 57:479–486
Sun M, Finnemann S, Febbraio M, Shan L, Annangudi S, Podrez E, Hoppe G, Darrow R, Organisciak D, Salomon R, Silverstein R, Hazen S (2006) J Biol Chem 281:4222–4230
Salomon R, Subbanagounder G, Singh U, O’Neil J, Hoff H (1997) Chem Res Toxicol 10:750–759
Brame C, Boutaud O, Davies S, Yang T, Oates J, Roden D, Roberts L 2nd (2004) J Biol Chem 279:13447–13451
Goyal J, Wang K, Liu M, Subbaiah P (1997) J Biol Chem 272:16231–16239
Ambati J, Anand A, Fernandez S, Sakurai E, Lynn B, Kuziel W, Rollins B, Ambati B (2003) Nature Med 9:1390–1397
Gottsch J, Bynoe L, Harlan J, Rencs E, Green W (1993) Arch Ophthalmol 111:126–129
Cousins S, Espinosa-Heidmann D, Alexandridou A, Sall J, Dubovy S, Csaky K (2002) Exp Eye Res 75:543–553
Malek G, Johnson L, Mace B, Saloupis P, Schmechel D, Rickman D, Toth C, Sullivan P (2005) Proc Natl Acad Sci U S A 102:11900–11905
Fox G, Kuwabara T, Wiggert B, Redmond T, Hess H, Chader G, Gery I (1987) Clin Immunol Immunopathol 43:256–264
Hirose S, Wiggert B, Redmond M, Kuwabara T, Nussenblatt R, Chader G, Gery I (1987) Exp Eye Res 45:695–702
de Kozak Y, Verwaerde C (2002) Int Rev Immunol 21:231–253
Caspi R, Chan C, Leake W, Higuchi M, Wiggert B, Chader G (1990) J Autoimmun 3:237–246
Caspi R (2003) Immunol Res 27:149–160
Nussenblatt R (2002) Int Rev Immunol 21:273–289
Acknowledgements
Supported by the State of Ohio BRTT Program, Columbus, Ohio; a Research Center Grant from the Foundation Fighting Blindness, Owings Mills, Maryland; a Challenge Grant from Research to Prevent Blindness, New York, NY; and by grants from the National Institutes of Health, Bethesda, Maryland, [EY014240 (JGH), EY015638 (JGH), EY014912 (VLP), and GM21249 (RGS)]. We thank Xiaoping (Annie) Yang, Mary E. Rayborn, Karen G. Shadrach, Vera L. Bonilha, and Yong Li for their help with the microscopy and immunology performed in these studies. We also thank Lisa Kuttner-Kondo, John W. Crabb, Bela Anand-Apte, and Neal S. Peachey for discussions and valuable comments during the course of these studies.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hollyfield, J.G., Perez, V.L. & Salomon, R.G. A Hapten Generated from an Oxidation Fragment of Docosahexaenoic Acid Is Sufficient to Initiate Age-Related Macular Degeneration. Mol Neurobiol 41, 290–298 (2010). https://doi.org/10.1007/s12035-010-8110-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12035-010-8110-z
Keyword
- Inflammation
- Retina
- Oxidative damage
- Age-related macular degeneration
- Fatty acid